Search results
Results from the WOW.Com Content Network
Home medical equipment is a category of devices used for patients whose care is being managed from a home or other private facility managed by a nonprofessional caregiver or family member. It is often referred to as "durable" medical equipment (DME) as it is intended to withstand repeated use by non-professionals or the patient, and is ...
Drugs.com is an online pharmaceutical encyclopedia that provides drug information for consumers and healthcare professionals, primarily in the United States. It self-describes its information as "accurate and independent" yet limited to being "for educational purposes only and is not intended for medical advice, diagnosis or treatment."
Induction chemotherapy is the first line treatment of cancer with a chemotherapeutic drug. This type of chemotherapy is used for curative intent. [1] [6]: 55–59 Combined modality chemotherapy is the use of drugs with other cancer treatments, such as surgery, radiation therapy, or hyperthermia therapy.
Starting Jan. 1, older adults on Medicare will spend no more than $2,000 a year on prescription drugs when a new price cap on out-of-pocket payments from the Inflation Reduction Act goes into effect.
(n) The term "durable medical equipment" includes iron lungs, oxygen tents, Nebulizers, CPAP, catheters, hospital beds, and wheelchairs (which may include a power-operated vehicle that may be appropriately used as a wheelchair, but only where the use of such a vehicle is determined to be necessary on the basis of the individual's medical and ...
Some breast cancer patients, particularly those with high-risk features such as a large number of involved lymph nodes, aggressive tumor biology, or those who do not respond adequately to standard adjuvant therapy, may be considered for HDC. However, the role of HDC in breast cancer is more controversial and is generally reserved for the ...
Cabozantinib was granted orphan drug status by the US Food and Drug Administration (FDA) in November 2010, [20] and in February 2017. [21]Exelixis filed a new drug application with the FDA in 2012, [22] and in November 2012, cabozantinib in its capsule formulation was granted marketing approval by the FDA under the name Cometriq for treating people with medullary thyroid cancer.
The list of 1997 drug labelling changes can be found on the FDA's website, here. The first patient package insert required by the FDA was in 1968, mandating that isoproterenol inhalation medication must contain a short warning that excessive use could cause breathing difficulties.